In this episode, we discuss Nvidia's strategic move to invest $50 million into Recursion, a company at the forefront of AI-enabled drug discovery. We examine how Nvidia's technology and Recursion's AI expertise could revolutionize the pharma industry.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.